A031702- A Phase II Study Of Ipilimumab , Cabozantinib, And Nivolumab In Rare Genitourinary Cancers (Iconic)
Posted Date: Jan 18, 2021
- Investigator: Shuchi Gulati
- Specialties: Cancer, Kidney Disease, Oncology
- Type of Study: Drug
The main purpose of this study is to evaluate the efficacy of cabozantinib s-malate (cabozantinib) combined with nivolumab and ipilimumab in the first or second-line (and beyond) setting for patients within each of the rare genitourinary (GU) variant histology group of interest, as measured by objective response rate (ORR).
Criteria:
To Be Eligible: Must Have Diagnosis Of A Metastatic Rare Gu Cancer, Be Able To Swallow Oral Tablets, Adequate Organ Function, No Chemo Or Radiation Within 2 Weeks, No Evidence Of Tumor Invading Gi Tract Or Major Blood Vessels, No Uncontrolled, Significant Intercurrent Or Recent Illness Or Infection That May Impact Safety On The Study
Keywords:
Genitourinary Cancers, Gu, Rare
For More Information:
Uc Cancer Center
513-584-7658
cancer@uchealth.com